Results 181 to 190 of about 48,719 (218)

The effect of treatment cessation on HBsAg negativity in HBeAg-negative chronic hepatitis B patients treated with nucleos(t)id analogues for more than three years. [PDF]

BMC Infect Dis
Senol Yilmaz A, Turker N.
europepmc   +1 more source

A Golgi‐localized N‐methyltransferase and reversible aldo–keto reductases coordinate dual terminal routes in galanthamine biosynthesis

The Plant Journal, Volume 126, Issue 6, June 2026.
Significant Statement This study identifies LaTMT2, a Golgi‐localized N‐methyltransferase, and three reversible aldo–keto reductases (LaAKR1 and LaAKR3) as key enzymes coordinating the dual terminal routes of galanthamine biosynthesis in Leucojum aestivum.
Basanta Lamichhane, Archana Niraula, Natacha Merindol, Sarah‐Eve Gélinas, Patrick Lagüe, Simon Ricard, Hugo Germain, Isabel Desgagné‐Penix   +7 more
wiley   +1 more source

Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B. [PDF]

Ann Med
Wang HW, Lai HC, Hsu WF, Chen SH, Kuo YC, Peng CY.   +5 more
europepmc   +1 more source

Modifying def2‐TZVPP: A Minimal Diffuse Addition for Reliable ΔE Versus ρ(BCP) Relationships in H‐Bonded Systems

Journal of Computational Chemistry, Volume 47, Issue 14, 30 May 2026.
Minimal hydrogen‐centered diffuse functions improve the description of the hydrogen‐bond critical point. ABSTRACT Basis set quality has a relevant role in the electronic structure description of hydrogen‐bonded (H‐bonded) systems, particularly for properties sensitive to the electron density in low‐density intermolecular regions.
Murillo H. Queiroz, Tiago V. Alves, Diego F. S. Paschoal, Roberto Rivelino   +3 more
wiley   +1 more source

Different nucleos(t)ide analogs in resected hepatitis B virus-associated hepatocellular carcinoma: a systematic review. [PDF]

Front Pharmacol
Qiu H, Zhang Y, Xu F, Xue S.
europepmc   +1 more source

Monitoring Adherence and Renal Safety of Nucleos(t)ide Analogs for Patients With Chronic Hepatitis B. [PDF]

Clin Transl Gastroenterol
Hsu CC, Chen ZE, Chao FH, Chou CY, Chang YL, Chou YC, Hou MC, Wu JC, Su CW.   +8 more
europepmc   +1 more source

On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 years. [PDF]

J Gastroenterol
Hosaka T, Hikita H, Tahata Y, Yamada R, Murai K, Miyazaki M, Ishida H, Hosui A, Sakamori R, Tatsumi N, Doi Y, Ohkawa K, Egawa S, Nawa T, Nozaki Y, Imanaka K, Nakahara M, Sakakibara M, Yakushijin T, Yoshida Y, Ogawa H, Usui T, Matsumoto K, Maesaka K, Shirai K, Makino Y, Saito Y, Kodama T, Takehara T.   +28 more
europepmc   +1 more source

Doxecitine and Doxribtimine: First Approval. [PDF]

Paediatr Drugs
Blair HA.
europepmc   +1 more source

Risk factors and predicted model for clinical relapse after antiviral therapy cessation in chronic hepatitis B patients: a retrospective real-world data analysis. [PDF]

Biomed Eng Online
Zhang X, Mao M, Zhang Y, Li X.
europepmc   +1 more source

Association between deletions in the preS1/2 region of the hepatitis B virus genome and persistently abnormal ALT levels in patients with chronic hepatitis B treated with nucleos(t)ide analogs. [PDF]

Arch Virol
Sato Y, Doi K, Inoue J, Ninomiya M, Tsuruoka M, Sato K, Onuki M, Sawahashi S, Ouchi K, Watanabe K, Niitsuma H, Masamune A.   +11 more
europepmc   +1 more source